Glenmark reaches $37.8 million settlement in US price-fixing case over generic drugs
MLex Summary: Glenmark Pharmaceutical agreed to pay $37.8 million to resolve US price-fixing claims filed by direct purchasers. The deal is subject to approval by a federal judge. See attached file. ...To view the full article, register now.
Already a subscriber? Click here to view full article